Potassium Hydroxide → 1-(4-((1-(tert-Butoxycarbonyl)piperidin-3-yl)methylamino)-6-(5-cyanopyrazin-2-ylamino)pyridin-3-yl)-1H-pyrrole-3-carboxylic acid

HRID 556827Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 556827
[C:1]([C:3]1[N:4]=[CH:5][C:6]([NH:9][C:10]2[CH:15]=[C:14]([NH:16][CH2:17][CH:18]3[CH2:23][CH2:22][CH2:21][N:20]([C:24]([O:26][C:27]([CH3:30])([CH3:29])[CH3:28])=[O:25])[CH2:19]3)[C:13]([N:31]3[CH:35]=[CH:34][C:33]([C:36]([O:38]CC)=[O:37])=[CH:32]3)=[CH:12][N:11]=2)=[N:7][CH:8]=1)#[N:2].[OH-].[K+]>C(O)C>[C:27]([O:26][C:24]([N:20]1[CH2:21][CH2:22][CH2:23][CH:18]([CH2:17][NH:16][C:14]2[CH:15]=[C:10]([NH:9][C:6]3[CH:5]=[N:4][C:3]([C:1]#[N:2])=[CH:8][N:7]=3)[N:11]=[CH:12][C:13]=2[N:31]2[CH:35]=[CH:34][C:33]([C:36]([OH:38])=[O:37])=[CH:32]2)[CH2:19]1)=[O:25])([CH3:30])([CH3:28])[CH3:29]

Komponenten

4

Edukt 2

HCID 14797Potassium HydroxideHCID 71022175tert-Butyl 3-((2-(5-cyanopyrazin-2-ylamino)-5-(3-(ethoxycarbonyl)-1H-pyrrol-1-yl)pyridin-4-ylamino)methyl)piperidine-1-carboxylate

Produkt 1

HCID 667465061-(4-((1-(tert-Butoxycarbonyl)piperidin-3-yl)methylamino)-6-(5-cyanopyrazin-2-ylamino)pyridin-3-yl)-1H-pyrrole-3-carboxylic acid

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 702EthanolLösungsmittel

Reaktionsbedingungen

Temperatur
50 °C

Versuchsvorschrift

tert-Butyl 3-((2-(5-cyanopyrazin-2-ylamino)-5-(3-(ethoxycarbonyl)-1H-pyrrol-1-yl)pyridin-4-ylamino)methyl)piperidine-1-carboxylate (42 mg, 0.077 mmol) was dissolved in ethanol (1 mL). KOH (43 mg, 0.770 mmol) was added and the solution was stirred at 50° C. for 72 h. The reaction mixture was evaporated to dryness and the residue was partitioned between water and dichloromethane. The two phases were separated and the organic phase was extracted with water. The combined aqueous phases were neutralised to pH 7 by the addition of 1M HCl and then evaporated to dryness. The product (7 mg, 17%) was used directly in the next step without further purification.

Aufarbeitung

  1. customThe reaction mixture was evaporated to dryness
  2. customthe residue was partitioned between water and dichloromethane
  3. customThe two phases were separated
  4. extractionthe organic phase was extracted with water
  5. additionThe combined aqueous phases were neutralised to pH 7 by the addition of 1M HCl
  6. customevaporated to dryness
  7. customThe product (7 mg, 17%) was used directly in the next step without further purification

Quellen und Nachweise

ORD-Eintrag
ord-ec5d720f22c041afab7b751147f98287
Quelldatensatz
uspto-grants-2011_11
Patentnummer
US08058045B2

Notizen zur Reaktion

Wird geladen…